S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in

Carbios SAS Stock Forecast, Price & News

-0.40 (-0.89 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $44.50
50-Day Range
MA: $37.56
52-Week Range
Now: $44.50
Volume718 shs
Average Volume3,455 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Carbios SAS, a green chemistry company, develops industrial bioprocesses for the biodegradation and bio recycling of polymers. The company produces enzymated pellets for use in the production of biosourced and biodegradable plastics. It also recycles plastic waste into plastic materials; and produces polylactic acid. Carbios SAS has a development agreement with Novozymes to produce enzyme for recycling of PET-plastics and fibers. The company was founded in 2011 and is headquartered in Saint-Beauzire, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Specialty Chemicals
Phone33 4 73 86 51 76



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.40 (-0.89 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive COOSF News and Ratings via Email

Sign-up to receive the latest news and ratings for COOSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Carbios SAS (OTCMKTS:COOSF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Carbios SAS?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carbios SAS in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Carbios SAS

What stocks does MarketBeat like better than Carbios SAS?

Wall Street analysts have given Carbios SAS a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Carbios SAS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Carbios SAS?

Carbios SAS saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 2,100 shares, an increase of 2,000.0% from the October 15th total of 100 shares. Based on an average trading volume of 2,500 shares, the short-interest ratio is currently 0.8 days.
View Carbios SAS's Short Interest

Who are some of Carbios SAS's key competitors?

Who are Carbios SAS's key executives?

Carbios SAS's management team includes the following people:
  • Mr. Jean-Claude Lumaret, CEO, CTO & Director (Age 62)
  • Mr. Kader Hidra, Chief Financial Officer
  • Prof. Alain Marty, Member of Scientific Advisory Board & Chief Scientific Officer
  • Mr. Emmanuel Maille, Director of Strategy & Devel.
  • Mr. Martin Stephan, Deputy Chief Exec. Officer

What is Carbios SAS's stock symbol?

Carbios SAS trades on the OTCMKTS under the ticker symbol "COOSF."

How do I buy shares of Carbios SAS?

Shares of COOSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Carbios SAS's stock price today?

One share of COOSF stock can currently be purchased for approximately $44.50.

What is Carbios SAS's official website?

The official website for Carbios SAS is www.carbios.fr.

How can I contact Carbios SAS?

The company can be reached via phone at 33 4 73 86 51 76.

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.